More affordable Zepbound? Lilly’s new pricing plan shakes up obesity treatment
Eli Lilly and Company (Lilly) has introduced new single-dose vials of Zepbound (tirzepatide), expanding treatment options for self-pay patients seeking obesity medications. The company’s latest ... Read More
Adial Pharmaceuticals secures FDA support for AD04 as Phase 3 clinical trials move forward
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in addiction treatment development, has received a pivotal endorsement from the U.S. Food and Drug Administration (FDA) ... Read More
MeiraGTx’s rAAV8.hRKp.AIPL1 shows remarkable efficacy in treating severe retinal dystrophy
A gene therapy developed by MeiraGTx Holdings plc has demonstrated remarkable success in restoring vision to children born blind due to severe retinal dystrophy. The ... Read More
NKGen Biotech administers first dose of troculeucel for FTD under FDA-cleared compassionate use
NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in natural killer cell therapy, has taken a significant step in the treatment of frontotemporal ... Read More
Inozyme Pharma presents positive interim data on INZ-701 at CHOP Cardiology 2025
Inozyme Pharma Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases affecting bone health and blood vessels, has presented promising ... Read More
GSK secures FDA approval for 5-in-1 meningococcal vaccine to expand protection for adolescents
GSK has received approval from the US Food and Drug Administration (FDA) for PENMENVY, a 5-in-1 meningococcal vaccine designed to protect against the five most ... Read More
Kexing Biopharm secures FDA IND approval for GB05, advancing pediatric RSV treatment
Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) has received Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA) for GB05, ... Read More
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and relatlimab-rmbw) for adjuvant melanoma treatment, failed to ... Read More
Can Thykamine change the future of MASH treatment? Devonian Health Group says yes!
Devonian Health Group Inc. (TSXV: GSD; OTCQB: DVHGF), a clinical-stage pharmaceutical company, has announced promising preclinical results for its proprietary drug candidate, Thykamine, in MASH ... Read More
Moleculin Biotech moves forward with pivotal Annamycin trial in AML after FDA backing
Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing innovative treatments for acute myeloid leukemia, has received critical guidance from the U.S. ... Read More